Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
$3.37
0.020.60%
At close: -
$3.41
0.041.19%
After Hours: 5:32 PM EDT
Comments
Loading...
Corvus Pharma Analyst Ratings and Price Targets | NASDAQ:CRVS | Benzinga
Corvus Pharmaceuticals Inc has a consensus price target of $10.8 based on the ratings of 6 analysts. The high is $21 issued by Ladenburg Thalmann on September 16, 2024. The low is $3.5 issued by Mizuho on March 27, 2024. The 3 most-recent analyst ratings were released by Oppenheimer, HC Wainwright & Co., and HC Wainwright & Co. on March 26, 2025, March 26, 2025, and January 14, 2025, respectively. With an average price target of $12.33 between Oppenheimer, HC Wainwright & Co., and HC Wainwright & Co., there's an implied 261.68% upside for Corvus Pharmaceuticals Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Oppenheimer
HC Wainwright & Co.
Ladenburg Thalmann
Mizuho
Mizuho
1calculated from analyst ratings
Analyst Ratings for Corvus Pharma
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 03/26/2025 | Buy Now | 339.88% | Oppenheimer | Jeff Jones33% | $14 → $15 | Maintains | Outperform | Get Alert |
| 03/26/2025 | Buy Now | 222.58% | HC Wainwright & Co. | Sean Lee68% | $11 → $11 | Reiterates | Buy → Buy | Get Alert |
| 01/14/2025 | Buy Now | 222.58% | HC Wainwright & Co. | Sean Lee68% | $11 → $11 | Reiterates | Buy → Buy | Get Alert |
| 01/02/2025 | Buy Now | 222.58% | HC Wainwright & Co. | Sean Lee68% | → $11 | Initiates | → Buy | Get Alert |
| 11/13/2024 | Buy Now | 310.56% | Oppenheimer | Jeff Jones33% | $8 → $14 | Reiterates | Outperform → Outperform | Get Alert |
| 09/16/2024 | Buy Now | 515.84% | Ladenburg Thalmann | Aydin Huseynov35% | $12 → $21 | Maintains | Buy | Get Alert |
| 05/07/2024 | Buy Now | 134.6% | Oppenheimer | Jeff Jones33% | $7 → $8 | Maintains | Outperform | Get Alert |
| 04/01/2024 | Buy Now | — | Cantor Fitzgerald | Li Watsek41% | — | Reiterates | → Overweight | Get Alert |
| 03/27/2024 | Buy Now | 2.64% | Mizuho | Graig Suvannavejh55% | $3.5 → $3.5 | Maintains | Neutral | Get Alert |
| 03/20/2024 | Buy Now | 105.28% | Oppenheimer | Jeff Jones33% | $8 → $7 | Maintains | Outperform | Get Alert |
| 09/07/2023 | Buy Now | 17.3% | Cantor Fitzgerald | Li Watsek41% | → $4 | Reiterates | Overweight → Overweight | Get Alert |
| 06/16/2023 | Buy Now | 2.64% | Mizuho | Mara Goldstein55% | → $3.5 | Reiterates | Neutral → Neutral | Get Alert |
| 05/30/2023 | Buy Now | 193.26% | Ladenburg Thalmann | Aydin Huseynov35% | $4 → $10 | Maintains | Buy | Get Alert |
| 05/09/2023 | Buy Now | 17.3% | Cantor Fitzgerald | Li Watsek41% | $2 → $4 | Maintains | Overweight | Get Alert |
| 03/30/2023 | Buy Now | 2.64% | Mizuho | Mara Goldstein55% | → $3.5 | Reiterates | → Neutral | Get Alert |
| 10/07/2022 | Buy Now | -41.35% | Ladenburg Thalmann | Aydin Huseynov35% | → $2 | Initiates | → Buy | Get Alert |
FAQ
What is the target price for Corvus Pharma (CRVS) stock?
The latest price target for Corvus Pharma (NASDAQ:CRVS) was reported by Oppenheimer on March 26, 2025. The analyst firm set a price target for $15.00 expecting CRVS to rise to within 12 months (a possible 339.88% upside). 8 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Corvus Pharma (CRVS)?
The latest analyst rating for Corvus Pharma (NASDAQ:CRVS) was provided by Oppenheimer, and Corvus Pharma maintained their outperform rating.
When was the last upgrade for Corvus Pharma (CRVS)?
There is no last upgrade for Corvus Pharma
When was the last downgrade for Corvus Pharma (CRVS)?
There is no last downgrade for Corvus Pharma.
When is the next analyst rating going to be posted or updated for Corvus Pharma (CRVS)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Corvus Pharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Corvus Pharma was filed on March 26, 2025 so you should expect the next rating to be made available sometime around March 26, 2026.
Is the Analyst Rating Corvus Pharma (CRVS) correct?
While ratings are subjective and will change, the latest Corvus Pharma (CRVS) rating was a maintained with a price target of $14.00 to $15.00. The current price Corvus Pharma (CRVS) is trading at is $3.41, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.